공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

외분비 췌장기능부전 : 파이프라인 리뷰

Exocrine Pancreatic Insufficiency - Pipeline Review, H2 2017

리서치사 Global Markets Direct
발행일 2017년 12월 상품 코드 293887
페이지 정보 영문 44 Pages
가격
US $ 2,000 ₩ 2,276,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,553,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 6,830,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


외분비 췌장기능부전 : 파이프라인 리뷰 Exocrine Pancreatic Insufficiency - Pipeline Review, H2 2017
발행일 : 2017년 12월 페이지 정보 : 영문 44 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

외분비 췌장기능부전(EPI)은 췌외분비효소의 결핍을 특징으로 하는 질환으로 소화불량을 일으킵니다. 설사, 연변, 지방분이 흡수되지 않은 지방변, 비타민 결핍, 식욕 부진, 원인 불명 체중 감소 등의 증상이 있습니다. 치료에는 췌장효소 보충요법(PERT), 생활 습관 개선 등이 있습니다.

세계의 외분비 췌장기능부전(Exocrine Pancreatic Insufficiency) 치료제 파이프라인 제품에 대해 조사했으며, 현재의 개발 파이프라인 상황과 최신 동향, 후기 단계 및 중지된 프로젝트, 주요 기업과 개발중인 제품 등의 정보를 전해드립니다.

서론

  • 조사 범위

외분비 췌장기능부전 개요

치료제 개발

  • 파이프라인 제품 개요
  • 기업별 파이프라인
  • 기업에서 개발중인 제품

치료제 평가

  • 표적별
  • 작용기서별
  • 투여 경로별
  • 분자 종류별

외분비 췌장기능부전 : 치료제 개발에 참여하고 있는 기업

  • Anthera Pharmaceuticals Inc
  • Celleron Therapeutics Ltd
  • Cilian AG
  • Laboratoires Mayoly Spindler SAS
  • Nordmark Arzneimittel GmbH & Co KG

약제 개요

휴지중인 프로젝트

중지된 프로젝트

제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

도표

KSM 17.07.24

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Exocrine Pancreatic Insufficiency - Pipeline Review, H2 2017, provides an overview of the Exocrine Pancreatic Insufficiency (Gastrointestinal) pipeline landscape.

Exocrine pancreatic insufficiency (EPI) is a condition characterized by deficiency of the exocrine pancreatic enzymes, resulting in the inability to digest food properly, or maldigestion. Symptoms include diarrhea, loose, oily stools with unabsorbed fat (steatorrhea), vitamin deficiencies, loss of appetite, and unexplained weight loss. Treatment includes pancreatic enzyme replacement therapy (PERT) and lifestyle modifications.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Exocrine Pancreatic Insufficiency - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Exocrine Pancreatic Insufficiency (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Exocrine Pancreatic Insufficiency (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Exocrine Pancreatic Insufficiency and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 1 and 1 respectively.

Exocrine Pancreatic Insufficiency (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Exocrine Pancreatic Insufficiency (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Exocrine Pancreatic Insufficiency (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Exocrine Pancreatic Insufficiency (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Exocrine Pancreatic Insufficiency (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Exocrine Pancreatic Insufficiency (Gastrointestinal)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Exocrine Pancreatic Insufficiency (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Exocrine Pancreatic Insufficiency (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Exocrine Pancreatic Insufficiency - Overview
    • Exocrine Pancreatic Insufficiency - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Exocrine Pancreatic Insufficiency - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Exocrine Pancreatic Insufficiency - Companies Involved in Therapeutics Development
    • Anthera Pharmaceuticals Inc
    • Celleron Therapeutics Ltd
    • Cilian AG
    • Laboratoires Mayoly Spindler SAS
    • Nordmark Arzneimittel GmbH & Co KG
  • Exocrine Pancreatic Insufficiency - Drug Profiles
    • burlulipase - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cilase - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CXD-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • liprotamase - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MS-1819 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Exocrine Pancreatic Insufficiency - Dormant Projects
  • Exocrine Pancreatic Insufficiency - Discontinued Products
  • Exocrine Pancreatic Insufficiency - Product Development Milestones
    • Featured News & Press Releases
      • Dec 11, 2017: Anthera Pharmaceuticals Announces Positive Outcome of Interim Futility Analysis in the Phase 3 RESULT Clinical Study of Sollpura
      • Nov 09, 2017: Anthera Pharmaceuticals Announces Completion of Recruitment in the Phase 3 RESULT Clinical Study of Sollpura
      • Nov 02, 2017: Anthera Pharmaceuticals Announces Presentations of Sollpura Data at the North American Cystic Fibrosis Conference
      • Oct 20, 2017: AzurRx BioPharma and Mayoly Spindler Announce MS1819-SD Investigational Medicinal Product Dossier Submission
      • Sep 27, 2017: AzurRx BioPharma and Mayoly-Spindler Announce Positive MS1819-SD Phase II Data in Exocrine Pancreatic Insufficiency (EPI)
      • Sep 07, 2017: Anthera Pharmaceuticals Surpasses 50% Milestone for Screening of Patients in RESULT Phase 3 Clinical Study of Sollpura in Cystic Fibrosis
      • Aug 23, 2017: AzurRx Reaches 6th Patient Enrollment of Phase IIa Trial of MS1819 for Treatment of Exocrine Pancreatic Insufficiency Associated with Chronic Pancreatitis
      • Aug 14, 2017: Anthera Pharmaceuticals Announces RESULT Phase 3 Clinical Study of Sollpura will be Included in the European Cystic Fibrosis Clinical Trial Network
      • Jul 10, 2017: Anthera Pharmaceuticals Announces Phase 3 Clinical Study of Sollpura will be included in the Cystic Fibrosis Foundation Therapeutics Development Network
      • Jul 06, 2017: Anthera Announces Expansion of Screening in European Sites in Phase 3 RESULT Clinical Study of Sollpura
      • May 15, 2017: Anthera Announces First Patient Screened in RESULT Pivotal Phase 3 Clinical Study of Sollpura
      • Apr 11, 2017: AzurRx Provides Update on MS1819 Phase II Trial
      • Dec 21, 2016: AzurRx BioPharma Announces First Three Patients Included in Phase IIa Study with MS1819-SD for Endocrine Pancreatic Insufficiency
      • Nov 17, 2016: AzurRx BioPharma and Mayoly-Spindler Announce Initiation of Phase II Clinical Trial of MS1819-SD for Exocrine Pancreatic Insufficiency in Chronic Pancreatitis Patients
      • Jun 28, 2016: Anthera Provides Clinical Program Update for Sollpura
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Exocrine Pancreatic Insufficiency, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Exocrine Pancreatic Insufficiency - Pipeline by Anthera Pharmaceuticals Inc, H2 2017
  • Exocrine Pancreatic Insufficiency - Pipeline by Celleron Therapeutics Ltd, H2 2017
  • Exocrine Pancreatic Insufficiency - Pipeline by Cilian AG, H2 2017
  • Exocrine Pancreatic Insufficiency - Pipeline by Laboratoires Mayoly Spindler SAS, H2 2017
  • Exocrine Pancreatic Insufficiency - Pipeline by Nordmark Arzneimittel GmbH & Co KG, H2 2017
  • Exocrine Pancreatic Insufficiency - Dormant Projects, H2 2017
  • Exocrine Pancreatic Insufficiency - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Exocrine Pancreatic Insufficiency, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Targets, H2 2017
  • Number of Products by Stage and Targets, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top
전화 문의
F A Q